Company news
Adagene, Inc. news in 2025
Adagene, Inc.'s news releases, calls and decks from 2025, newest first.
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025